GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innoviva Inc (NAS:INVA) » Definitions » FCF Yield %

Innoviva (Innoviva) FCF Yield % : 15.37 (As of May. 16, 2024)


View and export this data going back to 2004. Start your Free Trial

What is Innoviva FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Innoviva's Trailing 12-Month Free Cash Flow is $152.0 Mil, and Market Cap is $989.1 Mil. Therefore, Innoviva's FCF Yield % for today is 15.37%.

The historical rank and industry rank for Innoviva's FCF Yield % or its related term are showing as below:

INVA' s FCF Yield % Range Over the Past 10 Years
Min: -13.06   Med: 10.18   Max: 32.98
Current: 15.37


During the past 13 years, the highest FCF Yield % of Innoviva was 32.98%. The lowest was -13.06%. And the median was 10.18%.

INVA's FCF Yield % is ranked better than
98.46% of 1554 companies
in the Biotechnology industry
Industry Median: -14.48 vs INVA: 15.37

Innoviva's FCF Margin % for the quarter that ended in Mar. 2024 was 47.80%.


Innoviva FCF Yield % Historical Data

The historical data trend for Innoviva's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innoviva FCF Yield % Chart

Innoviva Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
FCF Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.95 24.92 30.21 22.00 13.85

Innoviva Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.86 18.39 20.91 13.04 15.48

Competitive Comparison of Innoviva's FCF Yield %

For the Biotechnology subindustry, Innoviva's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Innoviva's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innoviva's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Innoviva's FCF Yield % falls into.



Innoviva FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Innoviva's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=140.653 / 1015.44428
=13.85%

Innoviva's annualized FCF Yield % for the quarter that ended in Mar. 2024 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=37.047 * 4 / 957.02628
=15.48%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Innoviva FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Innoviva FCF Yield % Related Terms

Thank you for viewing the detailed overview of Innoviva's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Innoviva (Innoviva) Business Description

Traded in Other Exchanges
Address
1350 Old Bayshore Highway, Suite 400, Burlingame, CA, USA, 94010
Innoviva Inc develops biopharmaceutical drugs in the antibiotic, respiratory, and digestive realms. Theravance's respiratory compounds are in late-stage trials for asthma and chronic obstructive pulmonary disease. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others. The firm collaborates with and receives funding from GlaxoSmithKline.
Executives
Marianne Zhen officer: Chief Accounting Officer C/O INNOVIVA, INC., 2000 SIERRA POINT PARKWAY, SUITE 500, BRISBANE CA 94005
Stephen Basso officer: Chief Financial Officer C/O INOZYME PHARMA, INC., 321 SUMMER STREET, SUITE 400, BOSTON MA 02210
Margaret Koziel officer: Chief Medical Officer C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Alexander J Denner 10 percent owner C/O SARISSA CAPITAL MANAGEMENT LP, 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Deborah Birx director 3300 LOWELL STREET NW, WASHINGTON DC 20008
Sarissa Capital Management Lp 10 percent owner 660 STEAMBOAT ROAD, GREENWICH CT 06830
Pavel Raifeld officer: Chief Executive Officer 1350 OLD BAYSHORE HIGHWAY, SUITE 400, BURLINGAME CA 94010
Sapna Srivastava director C/O MYOS CORPORATION, 45 HORSEHILL ROAD, SUITE 106, CEDAR KNOLLS NJ 07927
Larry G. Edwards officer: CEO of La Jolla Pharmaceutical C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472
Plc Glaxosmithkline 10 percent owner 980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0 TW8 9GS
Mark Dipaolo director 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Kostas D Odysseas director 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Sarah J. Schlesinger director C/O ARIAD PHARMACEUTICALS, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Jules Haimovitz director 601 108TH AVENUE NE, SUITE 1200, BELLEVUE WA 98004
George Bickerstaff director C/O VION PHARMACEUTICALS, INC., 4 SCIENCE PARK, NEW HAVEN CT 06511

Innoviva (Innoviva) Headlines